Dotmatics Overview
Pro stress-test →Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making, combining a workflow and data platform with best-of-breed applications to offer end-to-end solutions for biology, chemistry, formulations, data management, flow cytometry, and more. Trusted by more than 2 million researchers from the world's leading biopharma, chemicals and materials enterprises, and academic institutions, the company serves a massive addressable market in scientific R&D digital transformation.
Strategic Profile
Pro stress-test →Dotmatics released its flagship multimodal drug discovery platform named Luma in October 2023, a low-code SaaS platform that aggregates relevant data across instruments and software into clean data structures for AI and ML-based analysis. In April 2025, Siemens announced it will acquire Dotmatics for $5.1B from Insight Partners, validating the company's strategic position as the leader in AI-driven R&D platform consolidation.
Competitive Landscape
Pro stress-test →Dotmatics is the largest provider of R&D software for scientists and labs that helps with data analysis, genomics, assay development, flow cytometry, sequence analysis, cloning, computational fluid dynamics, protein characterization, materials development, formulations, and more. Direct competitors include specialized point solutions in cheminformatics (ChemDraw, Biovia), electronic lab notebooks (Benchling, Labguru), and data management platforms (PerkinElmer, Scilife), though Dotmatics' integrated platform approach and scale (2M+ users) provide a structural competitive advantage.
Industry Context
Dotmatics operates in R&D scientific software platforms.
Key facts
Founded: 2005 · Headquarters: Boston, US · Employees: 800+ · Revenue: N/A · Market cap: N/A